Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT05201612	TitlePembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).	Phase Phase 2	Date Added 2022-01-21	Location Spain	Prior IO Allowed No	CRC-directed Yes	Status Unknown status	Drugs Olaparib, Pembrolizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03088150	TitleCOLLISION Trial – Colorectal Liver Metastases: Surgery vs Thermal Ablation	Phase Phase 3	Date Added 2017-03-23	Location Netherlands	Prior IO Allowed Yes	CRC-directed Yes	Status Unknown status	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04483219	TitleTyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.	Phase Phase 2	Date Added 2020-07-23	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Unknown status	Drugs TKI ± anti-PD-1 antibody	Tags MSS/ MMRp
NCT ID NCT05409417	TitleExploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status	Phase Phase 2	Date Added 2022-06-08	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Unknown status	Drugs Bevacizumab, cetuximab, FOLFOX, Tislelizumab, XELOX	Tags MSS/ MMRp
NCT ID NCT05491317	TitleA Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors	Phase Phase 1, Phase 2	Date Added 2022-08-08	Location France	Prior IO Allowed Yes	CRC-directed No	Status Terminated	Drugs Pembrolizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05328908	TitleA Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer	Phase Phase 3	Date Added 2022-04-14	Location Arkansas, United States California, United States Connecticut, United States Florida, United States Georgia, United States Idaho, United States Indiana, United States Massachusetts, United States Michigan, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Virginia, United States Wisconsin, United States Argentina Australia Austria Belgium Canada Chile China Czechia France Germany Italy Japan Korea, Republic of Netherlands Poland Puerto Rico Singapore Spain Sweden Switzerland Taiwan	Prior IO Allowed No	CRC-directed Yes	Status Terminated	Drugs Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga	Tags MSS/ MMRp
NCT ID NCT05194735	TitlePhase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors	Phase Phase 1, Phase 2	Date Added 2022-01-18	Location Texas, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Terminated	Drugs Aldesleukin (IL-2), Neoantigen specific TCR-T cell drug product	Tags MSS/ MMRp
NCT ID NCT03547999	TitleA Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC	Phase Phase 2	Date Added 2018-06-06	Location California, United States Florida, United States Kansas, United States New Jersey, United States Ohio, United States Oregon, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Terminated	Drugs FPV-CV301, mFOLFOX6, MVA-BN-CV301, Nivolumab	Tags MSS/ MMRp
NCT ID NCT06039384	TitleA Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation	Phase Phase 1	Date Added 2023-09-15	Location California, United States Colorado, United States Michigan, United States Texas, United States Virginia, United States Italy Spain United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Terminated	Drugs Adagrasib, INCB099280	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05743036	TitleZN-c3 in Adult Participants With BRAF mutant Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2023-02-24	Location California, United States Kansas, United States Texas, United States Australia Germany Hungary Italy Poland Spain	Prior IO Allowed Yes	CRC-directed Yes	Status Terminated	Drugs cetuximab, encorafenib, ZN-c3	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 1 to 10 of 299 entries